Compounds > 4'-thiothymidine
Page last updated: 2024-12-06

4'-thiothymidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-thiothymidine is a nucleoside analog that has been studied as a potential antiviral agent. It is a synthetic analog of thymidine, a naturally occurring nucleoside found in DNA. The sulfur atom in the 4'-position of the sugar moiety is thought to be responsible for its antiviral activity. 4'-thiothymidine has been shown to inhibit the replication of a variety of viruses, including herpes simplex virus, cytomegalovirus, and human immunodeficiency virus. The mechanism of its antiviral action is thought to involve the inhibition of viral DNA polymerase, which is an enzyme essential for viral replication. 4'-thiothymidine has also been investigated for its potential anticancer activity. Studies have shown that it can inhibit the growth of various cancer cell lines. It is currently under investigation for its potential therapeutic use in treating viral infections and cancer.'

4'-thiothymidine: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10923208
CHEMBL ID463660
SCHEMBL ID6266871
MeSH IDM0191853
PubMed CID72371
CHEMBL ID445596
SCHEMBL ID1942500
MeSH IDM0191853

Synonyms (17)

Synonym
1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl]-5-methyl-pyrimidine-2,4-dione
134111-35-6
4'-thiothymidine
CHEMBL463660
SCHEMBL6266871
1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]-5-methylpyrimidine-2,4-dione
134111-33-4
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl]-5-methyl-pyrimidine-2,4-dione
brn 4322066
thymidine, 4'-thio-
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]-5-methylpyrimidine-2,4-dione
CHEMBL445596
SCHEMBL1942500
IVUDHNYLTWOARV-XLPZGREQSA-N
4/'-thiothymidine
DTXSID20928454
1-(2-deoxy-4-thiopentofuranosyl)-4-hydroxy-5-methylpyrimidin-2(1h)-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID104471Inhibitory dose required to reduce the viability of MT-4 cells by 50%1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID104817Minimum inhibitory concentration required to reduce cytopathogenicity of human immunodeficiency virus-1 (HIV-1) in MT-4 cells by 50%; No activity below ID50 observed1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID105823Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-1 (HSV-1) in MRC -5 cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID105824Minimum inhibitory concentration required to reduce cytopathogenicity of Varicella Zoster Virus (VZV) in MRC-5 cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID218050Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-2 (HSV-2) in vero cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID79241The concentration required to produce a 50% inhibition of clone formation in human epidermoid carcinoma H-Ep-2 cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
AID217769Inhibitory dose required to reduce the viability of vero cells by 50%1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID381856Activity of 10 U/mL Escherichia coli thymidine phosphorylase assessed as drug phosphorylation after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Kinetic parameters and recognition of thymidine analogues with varying functional groups by thymidine phosphorylase.
AID105827Minimum inhibitory concentration required to reduce cytopathogenicity of cytomegalovirus (CMV) in MRC-5 cells by 50%; ND=Not determined1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID98517The concentration required to produce a 50% reduction in the rate of cell proliferation in murine leukemia L1210 cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
AID542166Antiviral activity against Vaccinia virus WR infected in HFF assessed as reduction of plaque formation after 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID543526Ratio of compound EC50 to cidofovir EC50 for Vaccinia virus Copenhagen2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID29739Toxicity of compound was measured after ip administration to mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID542163Antiproliferative activity against HFF after 3 days by coulter counter assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID542165Antiviral activity against Vaccinia virus Copenhagen infected in HFF assessed as reduction of plaque formation after 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID79241The concentration required to produce a 50% inhibition of clone formation in human epidermoid carcinoma H-Ep-2 cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
AID98517The concentration required to produce a 50% reduction in the rate of cell proliferation in murine leukemia L1210 cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
AID105826Minimum inhibitory concentration required to reduce cytopathogenicity of cytomegalovirus (CMV) in MRC-5 cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID44034The concentration required to inhibit cell growth to 50% of untreated controls in human T-cell leukemia CCRF-CEM cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
AID563744Antiviral activity against HSV2 MS infected in HFF after 3 days by plaque reduction assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID218050Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-2 (HSV-2) in vero cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID105824Minimum inhibitory concentration required to reduce cytopathogenicity of Varicella Zoster Virus (VZV) in MRC-5 cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID563745Antiproliferative activity against HFF after 3 days by Coulter counting analysis2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID542421Antiviral activity against Cowpox virus Brighton infected in HFF assessed as reduction of plaque formation after 3 days2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID217769Inhibitory dose required to reduce the viability of vero cells by 50%1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID22167Half life was measured in mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID563743Cytotoxicity against HFF after 3 days by MTS assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID542164Cytotoxicity against HFF after 7 days by neutral red uptake assay2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID543528Ratio of compound EC50 to cidofovir EC50 for Cowpox virus Brighton2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID563742Selectivity index, ratio of CC50 for HFF to EC50 for HSV2 MS infected in HFF2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID381856Activity of 10 U/mL Escherichia coli thymidine phosphorylase assessed as drug phosphorylation after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Kinetic parameters and recognition of thymidine analogues with varying functional groups by thymidine phosphorylase.
AID543527Ratio of compound EC50 to cidofovir EC50 for Vaccinia virus WR2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID105823Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-1 (HSV-1) in MRC -5 cells by 50%. 1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID104817Minimum inhibitory concentration required to reduce cytopathogenicity of human immunodeficiency virus-1 (HIV-1) in MT-4 cells by 50%; No activity below ID50 observed1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID104471Inhibitory dose required to reduce the viability of MT-4 cells by 50%1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
AID19860Maximum plasma level was measured in mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (33.33)18.2507
2000's8 (29.63)29.6817
2010's7 (25.93)24.3611
2020's3 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies3 (12.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other22 (88.00%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymidine
[no description available]		4.56240pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine
[no description available]		2.0410uridinesdrug metabolite;
fundamental metabolite;
human metabolite
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		7.1110aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.110mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
deoxycytidine
[no description available]		2.420pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyuridine
[no description available]		2.420pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cadmium
Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.		2.0210cadmium molecular entity;
zinc group element atom
2',3'-dideoxythymidine
[no description available]		2.0410
5'-amino-2',5'-dideoxythymidine
5'-amino-5'-deoxythymidine: RN given refers to parent cpd		2.0410
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		3.07402-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
3'-amino-2',3'-dideoxythymidine
[no description available]		2.0410
singlet oxygen
Singlet Oxygen: An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages.		2.1110chalcogen;
monoatomic oxygen;
nonmetal atom		macronutrient
brivudine
brivudine: anti-herpes agent		1.9710
6-thioguanosine
6-thioguanosine: RN given refers to cpd without isomeric designation		1.9810purine nucleoside
thiouridine
Thiouridine: A photoactivable URIDINE analog that is used as an affinity label.. 4-thiouridine : A thiouridine in which the oxygen replaced by sulfur is that at C-4.		2.420nucleoside analogue;
thiouridine		affinity label;
antimetabolite
deoxy-4-thiothymidine
4-thiothymidine: structure in first source		2.1110
4-thio-2'-deoxyuridine
4-thio-2'-deoxyuridine: RN in Chemline for 2-thio-isomer: 2i35059-12-2		2.0210
2'-deoxy-4'-thiocytidine
2'-deoxy-4'-thiocytidine: RN & structure given in first source		1.9710
oligonucleotides
[no description available]		2.0210
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		1.97102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		6.9810guanosines;
purines D-ribonucleoside		fundamental metabolite
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.0510carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
thymidine
[no description available]		2.0410pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
idoxuridine
[no description available]		2.4520organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
uridine
[no description available]		2.0410uridinesdrug metabolite;
fundamental metabolite;
human metabolite
deoxycytidine
[no description available]		2.0410pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyuridine
[no description available]		2.0410pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		2.4520phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
2',3'-dideoxythymidine
[no description available]		2.0410
5'-amino-2',5'-dideoxythymidine
5'-amino-5'-deoxythymidine: RN given refers to parent cpd		2.0410
3'-amino-2',3'-dideoxythymidine
[no description available]		2.0410
brivudine
brivudine: anti-herpes agent		1.9710
2'-deoxy-4'-thiocytidine
2'-deoxy-4'-thiocytidine: RN & structure given in first source		2.4120
st-246
tecovirimat: A potent and specific inhibitor of orthopoxvirus replication. It is used for the treatment of SMALLPOX and other orthopoxvirus infections, including MONKEYPOX under expanded access investigational new drug protocol (https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html).		2.0510
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.41202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ganciclovir
[no description available]		2.05102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Epidermoid
[description not available]		02.6930
Leukemia L 1210
[description not available]		02.6730
Leukemia, Lymphocytic, T Cell
[description not available]		02.3820
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.6930
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		03.0750
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		02.3820
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.3820
Cardiomyopathies, Primary
[description not available]		02.6320
Besnier-Boeck Disease
[description not available]		02.6320
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		02.6320
Sarcoidosis
An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.		02.6320
Hibernation, Myocardial
[description not available]		02.3110
Cancer of Skin
[description not available]		02.2510
Skin Neoplasms
Tumors or cancer of the SKIN.		02.2510
Glial Cell Tumors
[description not available]		02.1710
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.1710
B Virus Infection
[description not available]		02.4720
Recrudescence
[description not available]		02.1110
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.1110
Cancer of Head
[description not available]		02.1110
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.1110
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.1110
Disease Exacerbation
[description not available]		02.1110
Kahler Disease
[description not available]		02.1110
Plasma Cell Tumor
[description not available]		02.1110
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		07.1110
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.		02.1110
Experimental Neoplasms
[description not available]		02.0410
Vaccinia
The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.		02.0510
Cow Pox
[description not available]		02.0510
Infections, Poxviridae
[description not available]		02.0510